Return to Listing

9 result(s) for Myelodysplastic Syndrome

PI Name Protocol # Title
Emma Scott STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Kim-Hien Dao STUDY00015363 WEAR in Oregon: Defining risks of blood cancer development in a cohort of older women with clonal hematopoiesis and TET2 mutations. (Women Engaged in Advancing health Research in Oregon is a prospective epidemiology study)
Laura Newell STUDY00015619 A phase 1/2 study of Vadastuximab Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate -2 or high-risk Myelodysplastic Syndrome (MDS).
Rachel Cook STUDY00015953 A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Kim-Hien Dao STUDY00015977 [NCI CIRB] The National Myelodysplastic Syndromes (MDS) Study
Rachel Cook STUDY00015993 A Phase I Dose Finding Study Evaluating Safety and Feasibility of BPX-701 in Patients with Relapsed or Refractory Myeloid Neoplasm
Richard Maziarz STUDY00016189 A Phase 1 Non-Randomized, Open-Label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies
Uma Borate STUDY00016338 A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in combination with cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome With Wild-Type TP53
Elie Traer STUDY00016896 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Malignancies
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080